We are happy to have an international expert in the arena of the treatment of advanced prostate cancer joining us today. We are excited to talk to him about a new treatment that is extending the survival of men with advanced prostate cancer. Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. He is currently the Assistant Dean for Oncology at Tulane University's School of Medicine, Medical Director of the Tulane Cancer Center, and the Laborde Professor for Cancer Research. His medical practice and research have focused on prostate cancer since 1990 when he finished a fellowship at the National Cancer Institute. He has published over 300 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. He has lectured widely and, at last count, has given invited lectures in 28 countries. Dr. Sartor is a world-renown leader when it comes to the management of advanced prostate cancer, particularly in those patients who have failed initial therapies. Stay tuned for more! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show highlights: Dr. Sartor explains what it means to have advanced prostate cancer. Some of the initial therapies that are available for men with advanced prostate cancer. Some of the indicators that show the initial therapies for advanced disease are starting to fail. Dr. Sartor explains what theranostics is. Dr. Sartor describes the patient population for the VISION Trial and discusses the VISION Trial. Dr. Sartor explains what the VISION Trial demonstrated when looking at the new treatment for advanced prostate cancer. Dr. Sartor discusses the possibility of the new therapy becoming an option even earlier in the stages of prostate cancer. Dr. Sartor talks about toxicity associated with the new treatment for advanced prostate cancer. Dr. Sartor will stay on after the show to record some valuable bonus content for the upcoming Prostate Health Academy where he will go into even more detail about this new treatment. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link here, on our podcast website) Join our Facebook group Follow Dr. Pohlman on Twitter and Instagram Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content. You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related